Infliximab‐related Vasculitis in Patients Affected by Ulcerative Colitis

Pastore, Serena; Londero, Margherita; Gortani, Giulia; Abate, Maria Valentina; Marchetti, Federico; Leo, Grazia Di; Ventura, Alessandro

doi:10.1097/mpg.0b013e3181e5e198

Cited by 11 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They include anti-TNF drugs [9][10][11][12][13][14][15], propylthiouracil [16][17][18][19][20][21], levamisolecontaminated cocaine [22][23][24] and the new small molecules [25 && ,26 && ,27]. They include anti-TNF drugs [9][10][11][12][13][14][15], propylthiouracil [16][17][18][19][20][21], levamisolecontaminated cocaine [22][23][24] and the new small molecules [25 && ,26 && ,27].…”

Section: Vasculitismentioning

confidence: 99%

Drug-induced rheumatic diseases

Bukhari

2012

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Vasculitismentioning

confidence: 99%

Drug-induced rheumatic diseases

Bukhari

2012

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…Similar infections were also reported in a recent study of the efficacy and safety of adalimumab in pediatric patients with CD. 38 Aside from infections, biologic therapy has also been associated with neutropenia, 53 psoriasis, 54 and vasculitis 55 in pediatric patients with UC.…”

Section: Immunogenicity and Safety Of Biologic Medicationsmentioning

confidence: 99%

Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients

Albenberg¹,

Mamula²,

Kelsen

2012

PHMT

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic, inflammatory disease of the large intestine. In pediatric patients, UC is associated with significant morbidity including persistent symptoms affecting quality of life, hospitalizations, and surgery, and therapeutic strategies are limited. The advent of biologics, specifically anti-tumor necrosis factor-α medications, has been very beneficial for pediatric patients suffering from UC. Since the introduction of these therapies, there has been improvement in the rates of both remission as well as colectomy-free survival. However, there has been concern regarding the adverse events associated with these medications including the risk of infection and malignancy. The efficacy and safety of infliximab, the most frequently used biologic medication in pediatric patients with UC, will be the focus of this review.

show abstract

Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

Bie

Escher

Ridder

2012

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD). Nevertheless, adalimumab and certolizumab have been used off-label to treat refractory pediatric IBD. Over the past 10 years, anti-TNF treatment has been of great benefit to many pediatric IBD patients, but their use is not without risks (infections, autoimmune diseases, malignancies). Despite the growing experience with these drugs in children with IBD, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of anti-TNF drugs in pediatric IBD and to discuss the yet-unsolved issues.

show abstract

Infliximab‐related Vasculitis in Patients Affected by Ulcerative Colitis

Cited by 11 publications

References 12 publications

Drug-induced rheumatic diseases

Drug-induced rheumatic diseases

Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients

Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

Contact Info

Product

Resources

About